138 related articles for article (PubMed ID: 31836524)
1. Application of cytochrome P450 reactivity on the characterization of chemical compounds and its association with repeated-dose toxicity.
Watanabe M; Sasaki T; Takeshita JI; Kushida M; Shimizu Y; Oki H; Kitsunai Y; Nakayama H; Saruhashi H; Ogura R; Shizu R; Hosaka T; Yoshinari K
Toxicol Appl Pharmacol; 2020 Feb; 388():114854. PubMed ID: 31836524
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
[TBL] [Abstract][Full Text] [Related]
3. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver.
Burke MD; Thompson S; Weaver RJ; Wolf CR; Mayer RT
Biochem Pharmacol; 1994 Aug; 48(5):923-36. PubMed ID: 8093105
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K3 (menadione) redox cycling inhibits cytochrome P450-mediated metabolism and inhibits parathion intoxication.
Jan YH; Richardson JR; Baker AA; Mishin V; Heck DE; Laskin DL; Laskin JD
Toxicol Appl Pharmacol; 2015 Oct; 288(1):114-20. PubMed ID: 26212258
[TBL] [Abstract][Full Text] [Related]
6. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
Rendic SP; Peter Guengerich F
Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
[TBL] [Abstract][Full Text] [Related]
7. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Vignati L; Turlizzi E; Monaci S; Grossi P; Kanter Rd; Monshouwer M
Toxicology; 2005 Dec; 216(2-3):154-67. PubMed ID: 16169652
[TBL] [Abstract][Full Text] [Related]
8. One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450.
Goeptar AR; te Koppele JM; van Maanen JM; Zoetemelk CE; Vermeulen NP
Biochem Pharmacol; 1992 Jan; 43(2):343-52. PubMed ID: 1310854
[TBL] [Abstract][Full Text] [Related]
9. Reversible and time-dependent inhibition of the hepatic cytochrome P450 steroidal hydroxylases by the proestrogenic pesticide methoxychlor in rat and human.
Li HC; Mani C; Kupfer D
J Biochem Toxicol; 1993 Dec; 8(4):195-206. PubMed ID: 8114062
[TBL] [Abstract][Full Text] [Related]
10. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes.
Weber GF; Waxman DJ
Biochem Pharmacol; 1993 Apr; 45(8):1685-94. PubMed ID: 8484807
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
12. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
Liu LY; Han YL; Zhu JH; Yu Q; Yang QJ; Lu J; Guo C
Biomed Chromatogr; 2015 Mar; 29(3):437-44. PubMed ID: 25098274
[TBL] [Abstract][Full Text] [Related]
13. An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS.
Otten JN; Hingorani GP; Hartley DP; Kragerud SD; Franklin RB
Drug Metab Lett; 2011 Jan; 5(1):17-24. PubMed ID: 21198441
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.
Shimada T; Yamazaki H; Foroozesh M; Hopkins NE; Alworth WL; Guengerich FP
Chem Res Toxicol; 1998 Sep; 11(9):1048-56. PubMed ID: 9760279
[TBL] [Abstract][Full Text] [Related]
15. Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation.
Imaoka S; Terano Y; Funae Y
Arch Biochem Biophys; 1990 Apr; 278(1):168-78. PubMed ID: 2321956
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 (P450) isoenzyme specific dealkylation of alkoxyresorufins in rat brain microsomes.
Dhawan A; Parmar D; Dayal M; Seth PK
Mol Cell Biochem; 1999 Oct; 200(1-2):169-76. PubMed ID: 10569197
[TBL] [Abstract][Full Text] [Related]
17. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants.
Murray M; Field SL
Biochem Pharmacol; 1992 May; 43(10):2065-71. PubMed ID: 1599495
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cannabidiol-mediated cytochrome P450 inactivation.
Bornheim LM; Everhart ET; Li J; Correia MA
Biochem Pharmacol; 1993 Mar; 45(6):1323-31. PubMed ID: 8466552
[TBL] [Abstract][Full Text] [Related]
19. Development of GC-MS based cytochrome P450 assay for the investigation of multi-herb interaction.
Oh HA; Lee H; Kim D; Jung BH
Anal Biochem; 2017 Feb; 519():71-83. PubMed ID: 28007398
[TBL] [Abstract][Full Text] [Related]
20. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Drug Metab Dispos; 2003 Jul; 31(7):833-6. PubMed ID: 12814958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
